ArticleOral health & preventive dentistry2026
Detection of Signals for Smell and Taste Disorders Associated with Z-drugs: A Disproportionality Analysis of the FAERS Database.
Article in Oral health & preventive dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to detect and characterise signals of disproportionate reporting for smell and taste disorders associated with Z-drugs in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
methodsReports involving Z-drugs and smell/taste disorders were identified using the Standardised MedDRA Query (SMQ) 'Taste and smell disorders'. Disproportionality analyses were performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and information component (IC). Sex-stratified, age-stratified, and time-to-onset (TTO) analyses were also conducted.
resultsAmong 32,853 reports involving Z-drugs, 3,480 were classified as smell- or taste-related adverse events. Eszopiclone accounted for 97.6% of these reports and demonstrated a strong disproportionality signal. Dysgeusia was the predominant adverse event, whereas parosmia and the preferred term 'taste disorder' generated additional positive signals. Signal strength was greatest among adults aged 18 to 45 years, and parosmia showed stronger disproportionality among women. Most events were reported within 30 days after treatment initiation.
conclusionsFAERS data indicate a strong association between eszopiclone and smell/taste disorders, particularly dysgeusia. Parosmia emerged as an additional signal warranting clinical attention. Further epidemiological and mechanistic studies are needed to clarify the underlying mechanisms and clinical significance of these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.